Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14674 | 0.87 | — | — | |
| SCHEMBL19288013 | 0.86 | EPHX2 (0.38) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8902429 | 0.84 | LMNA (0.42) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL1617287 | 0.84 | — | — | |
| SCHEMBL25473017 | 0.82 | — | — | |
| SCHEMBL20388653 | 0.82 | — | — | |
| SCHEMBL16986039 | 0.80 | MLYCD (0.31) | — | |
| SCHEMBL5837521 | 0.80 | ALDH1A1 (0.33) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL17704771 | 0.79 | CHRM1 (0.36) | CHRM1ALDH1A1TSHRNFKB1THPO | |
| SCHEMBL9074850 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5618951-A | REACTING A CHLORODIFLUOROACETATE WITH A HALOSILANE USING AN UREA SILVENT AND A REDUCING AGENT | ELI LILLY AND COMPANY (US) | 1997-04-08 | — | — | US | claimed |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | ANIXA BIOSCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4183807-A1 | COPOLYMER AND HOT MELT COMPOSITIONS COMPRISING SAID COPOLYMER | Henkel AG & Co. KGaA (DE) | 2023-05-24 | — | — | EP | disclosed |
| WO-2021113679-A1 | DIMERIC COMPOUNDS AS STING AGONISTS | MERSANA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-9856349-B2 | Catalysts and methods for polymer synthesis | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2018-01-02 | — | — | US | disclosed |
| US-20170349762-A1 | WATER-BASED COATING AGENT COMPOSITION, WATER-BASED LUBRICATING FILM PAINT COMPOSITION COMPRISING SAME, AND MEMBER | DUPONT TORAY SPECIALTY MATERIALS KABUSHIKI KAISHA (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170073463-A1 | CATALYTIC CARBONYLATION CATALYSTS AND METHODS | NOVOMER, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9505878-B2 | Catalysts and methods for polymer synthesis | NOVOMER, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9327280-B2 | Catalytic carbonylation catalysts and methods | NOVOMER, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2016025865-A1 | METHODS OF PRODUCING ALKYLFURANS | MICROMIDAS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| EP-0584043-B1 | Process for the preparation of substituted benzenes and benzene sulfonic acid and derivatives thereof and a process for the preparation of N'N-substituted ureas | CIBA GEIGY AG (CH) | 1996-10-30 | — | — | EP | disclosed |
| US-5508402-A | Process for the preparation of N,N'-substituted ureas | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5464697-A | Substituted tetracyanoquinodimethanes, processes for their preparation and their use | CIBA-GEIGY CORPORATION (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0552586-B1 | Process for the production of cyclopropylmethylketone | CIBA GEIGY AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| US-5426232-A | Substituted tetracyanoquinodimethanes, processes for their preparation and their use | CIBA-GEIGY CORPORATION (US) | 1995-06-20 | — | — | US | disclosed |
| US-5349062-A | Charge tranfer compounds | CIBA-GEIGY CORPORATION (US) | 1994-09-20 | — | — | US | disclosed |
| EP-0584043-A1 | Process for the preparation of substituted benzenes and benzene sulfonic acid and derivatives thereof and a process for the preparation of N'N-substituted ureas | CIBA-GEIGY AG (CH) | 1994-02-23 | — | — | EP | disclosed |
| US-5281730-A | Substituted tetracyanoquinodimethanes, processes for their preparation and their use | CIBA-GEIGY CORPORATION (US) | 1994-01-25 | — | — | US | disclosed |
| US-5254739-A | Heating a-acetylbutyrolactone in presence of a halide | CIBA-GEIGY CORPORATION (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0552586-A1 | Process for the production of cyclopropylmethylketone | CIBA-GEIGY AG (CH) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | SERPINB1, PREP, PRCP | CHRM1 4869/4885CHRM2 4856/4885CHRM4 4833/4885 |
| US-20170073463-A1 | CATALYTIC CARBONYLATION CATALYSTS AND METHODS | CBR3, CBR1, EPHX2 | CHRM1 1818/4885CHRM2 2539/4885CHRM4 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.